Sandu Pharmaceuticals Ltd — Results, 28-05-2025: Result

Sandu Pharmaceuticals Limited has announced a board meeting to approve the financial results for the quarter and half-year. The company approved audited standalone and consolidated financials, noting that following the full sale of its stake in wholly owned subsidiary Sandu Phytoceuticals Private Limited in August 2024, consolidation is no longer required from December 2024 onwards. The Board has proposed a final dividend of Rs. 0.80 per share (8%). They appointed Swapnil J Dixit and Associates as Secretarial Auditors for five years and M/s Shekhar Joshi & Co as Cost Auditors for 2025-26. Promoter Akshath Finvest and Properties Private Limited has been reclassified to the public category. The company reported revenue from operations of Rs. 14.07 Cr and profit after tax of Rs. 0.33 Cr for the quarter, with year-end comprehensive income at Rs. 2.19 Cr. No subsidiary exists currently as Sandu Phytoceuticals has been struck off. The financials reflect the single business segment of Ayurvedic Proprietary Medicines.